AIM ImmunoTech (NYSEAMERICAN:AIM) Shares Down 2.7% – Time to Sell?

AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) shares were down 2.7% on Thursday . The company traded as low as $0.2150 and last traded at $0.2269. 10,380,839 shares changed hands during mid-day trading, a decline of 9% from the average session volume of 11,424,733 shares. The stock had previously closed at $0.2332.

Wall Street Analyst Weigh In

Separately, Ascendiant Capital Markets decreased their price target on shares of AIM ImmunoTech from $10.00 to $9.00 and set a “buy” rating on the stock in a report on Monday, June 1st. One investment analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $9.00.

AIM ImmunoTech Stock Performance

The company has a market cap of $6.75 million, a price-to-earnings ratio of -0.07 and a beta of 1.19. The company has a fifty day moving average of $0.25 and a two-hundred day moving average of $0.45.

AIM ImmunoTech (NYSEAMERICAN:AIM) last posted its earnings results on Friday, August 7th. The company reported ($0.43) earnings per share for the quarter. The business had revenue of $0.03 million for the quarter. Equities analysts expect that AIM ImmunoTech Inc. will post -0.78 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its stake in AIM ImmunoTech stock. DRW Securities LLC grew its stake in AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) by 60.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 69,545 shares of the company’s stock after buying an additional 26,254 shares during the period. DRW Securities LLC owned 2.12% of AIM ImmunoTech worth $79,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 12.02% of the company’s stock.

AIM ImmunoTech Company Profile

AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.

In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats.